Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Mol Cancer Ther. 2019 Sep 5;18(11):1916–1925. doi: 10.1158/1535-7163.MCT-18-1334

Figure 1: RX-5902 inhibits cellular proliferation in TNBC cell lines.

Figure 1:

TNBC cell lines were treated with RX-5902 (0-10 μmol/l) for 72 hours and cellular proliferation was assessed using the Cell Titer-Glo Luminescent Cell Viability Assay. Using an IC50 value cutoff of 100 nM, 14 cell lines were determined to be sensitive to RX-5902 (green) and 4 resistant (red). TNBC subtypes, p53 mutation, PTEN loss, PIK3CA mutation, BRCA1 mutation, KRAS mutation, RB1 mutation and CDKN2A mutation are included based on publicly available databases. TNBC molecular subtype was obtained from Lehmann et al, using gene expression profiles [50]. MSL; mesenchymal stem-like, M; mesenchymal, BL1; basal-like 1, BL2; basal-like 2, IM; immunomodulatory, LAR; luminal androgen receptor, UNK; unknown.